|
|
Additional
Resources
|
|
How To Prevent Hepatitis
Hepatitis is a very common disease that can cause a lot of damage to your liver. In cases of viral hepatitis, there are some ways of prevention, but this generally speaking.The most Read more...
|
|
|
|
Hepatitis
Sale Offers, Ephedra, And Weight Loss... Are You A Target?
By By Yogesh Rele
Today, Ephedra is an herb of controversy. It contains ephedrine, a stimulant alkaloid used in many weight loss medicines. This herb has been known by the Chinese for thousands of years where it was used for treating asthma. It was used by the Zuni Indians of New Mexico to treat the beginning stages of Syphilis.
Ephedra sinica has been brewed into a tasty tea and consumed for its powerful stimulating effects
in china for 2000 years. Chinese usage of ma huang dates to the first century A.D. It is intended to induce sweat, soothe breathing, and promote urine excretion. Ma Huang.
Ma huang is traditionally used to treat bronchial asthma, cold and flu, chills, lack of perspiration, headache, nasal congestion, aching joints and bones, coughing, wheezing, and edema.
When a capsule contains 10 mg of naturally occurring Ephedrine alkaloids. Because of its high yield of Ephedrine alkaloids it has many of the benefits of a bronchodilator, but opening airways and dramatically enhancing breathing performance can kill person instantly. Such products are not available in California, Illinois or New York State. The following is real blend of formula; anything other than below may be harmful for your health.
A 50 mg blend of Ephedra herb (Ma Huang) yielding 10mg ephedrine alkaloids
Remember; consult your physician before you're on such drugs.
We strive to provide only quality information, so
if
there is a specific topic related to hepatitis
that you would
like us to cover, please contact us at any time.
And again, thank you to those contributing daily to
our Hepatitis
Website, especially
regarding "hepatitis vaccine".
If you can't find the
Hepatitis information you are looking for?
Try Google Search
Hepatitis C Translating Initiatives for Depression Into Solutions
<b>Conditions</b>: Hepatitis C; Depression<br/><b>Intervention</b>: Other: Depression collaborative care model<br/><b>Sponsor</b>: Department of Veterans Affairs<br/><b>Not yet recruiting</b> - verified June 2010
Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure
<b>Condition</b>: Hepatitis C<br/><b>Intervention</b>: <br/><b>Sponsor</b>: Fundacion IMIM<br/><b>Recruiting</b> - verified November 2009
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
<b>Conditions</b>: Chronic Hepatitis C; Oxidative Stress<br/><b>Interventions</b>: Dietary Supplement: silymarin; Dietary Supplement: green tea extract (EGCG)<br/><b>Sponsors</b>: University of North Carolina, Chapel Hill; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health (NIH)<br/><b>Recruiting</b> - verified February 2010
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
<b>Condition</b>: Hepatitis C<br/><b>Intervention</b>: Drug: ribavirin pre-treatment<br/><b>Sponsor</b>: University of Roma La Sapienza<br/><b>Recruiting</b> - verified October 2009
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
<b>Condition</b>: Hepatitis C<br/><b>Intervention</b>: Drug: Pegylated interferon-alfa-2b and ribavirin<br/><b>Sponsor</b>: Region Skane<br/><b>Recruiting</b> - verified January 2010
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
<b>Condition</b>: Chronic Hepatitis C<br/><b>Intervention</b>: Drug: CT-011<br/><b>Sponsors</b>: CureTech Ltd; Teva Pharmaceutical Industries<br/><b>Recruiting</b> - verified September 2009
Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
<b>Conditions</b>: Hepatitis C, Chronic; Liver Diseases; Virus Diseases<br/><b>Intervention</b>: Drug: peginterferon alfa-2a and ribavirin<br/><b>Sponsors</b>: University of Ulm; Hoffmann-La Roche<br/><b>Completed</b> - verified January 2010
Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener on Viral Load in Treatment (TX) Naive Genotype 1 (GT 1) Subjects With Chronic Hepatitis C (CHC)
<b>Condition</b>: Hepatitis C<br/><b>Intervention</b>: Dietary Supplement: Mogroside sweetener (PureLo)<br/><b>Sponsor</b>: The Geneva Foundation<br/><b>Enrolling by invitation</b> - verified June 2009
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-Responder/Relapsers
<b>Conditions</b>: Chronic Hepatitis C; Genotype 1; Relapse<br/><b>Interventions</b>: Drug: Betaine; Drug: Peginterferon alpha 2a; Drug: Ribavirin<br/><b>Sponsor</b>: University of Nebraska<br/><b>Not yet recruiting</b> - verified April 2009
Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C
<b>Condition</b>: Chronic Hepatitis C<br/><b>Interventions</b>: Procedure: Blood sampling of peripheral blood mononuclear cells; Procedure: Blood draw, 20ml peripheral blood mononuclear cells<br/><b>Sponsor</b>: University of Nebraska<br/><b>Terminated</b> - verified January 2010
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
<b>Conditions</b>: Obesity; Insulin Resistance; Metabolic Syndrome; Hepatitis C<br/><b>Interventions</b>: Drug: Orlistat; Behavioral: Dietary and Lifestyle modification educational sessions<br/><b>Sponsor</b>: University of Pittsburgh<br/><b>Recruiting</b> - verified March 2009
TMC435350-TiDP16-C202: A Study to Assess the Activity of TMC435 on Hepatitis C Virus in Patients Who Have Never Received Treatment for Their Hepatitis C Infection.
<b>Conditions</b>: Hepatitis C, Chronic; Hepatitis C; Infection<br/><b>Intervention</b>: Drug: TMC435<br/><b>Sponsor</b>: Tibotec Pharmaceuticals, Ireland<br/><b>Completed</b> - verified April 2010
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
<b>Condition</b>: Hepatitis C<br/><b>Intervention</b>: <br/><b>Sponsor</b>: University of California, San Francisco<br/><b>Recruiting</b> - verified August 2009
A Study Evaluating 24-Week Telaprevir-Based Treatment, or Extended Treatment to 48 Weeks, in Chronic Hepatitis C Patients Who Achieve a Rapid Viral Response
<b>Condition</b>: Hepatitis C<br/><b>Interventions</b>: Drug: telaprevir; Drug: ribavirin; Biological: peginterferon alfa-2a<br/><b>Sponsors</b>: Vertex Pharmaceuticals Incorporated; Tibotec Pharmaceutical Limited<br/><b>Active, not recruiting</b> - verified January 2009
Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)(TERMINATED)
<b>Conditions</b>: Hepatitis C, Chronic; Hepacivirus<br/><b>Interventions</b>: Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908); Behavioral: Patient assistance program<br/><b>Sponsor</b>: Schering-Plough<br/><b>Terminated</b> - verified July 2008
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
<b>Condition</b>: Hepatitis C, Chronic<br/><b>Interventions</b>: Procedure: Liver Biopsy; Drug: Peginterferon & Ribavirin for Hepatitis C; Drug: Pre-treatment Ribavirin<br/><b>Sponsor</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified March 2010
HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
<b>Condition</b>: Chronic Hepatitis C<br/><b>Interventions</b>: Drug: Oral HDV-Interferon + ribavarin; Drug: Injectable HDV-Interferon + ribavarin<br/><b>Sponsor</b>: Hepasome Pharmaceuticals<br/><b>Active, not recruiting</b> - verified January 2009
Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation
<b>Conditions</b>: Hepatitis C Virus Infection; Liver Transplantation<br/><b>Intervention</b>: Procedure: Gradual immunosuppression drug withdrawal.<br/><b>Sponsor</b>: Hospital Clinic of Barcelona<br/><b>Recruiting</b> - verified December 2008
Hepatitis C Treatment and Atherosclerosis
<b>Conditions</b>: Chronic Hepatitis C; Atherosclerosis<br/><b>Intervention</b>: <br/><b>Sponsor</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified September 2009
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
<b>Condition</b>: Chronic Hepatitis C<br/><b>Interventions</b>: Drug: pegylated interferon alpha and plus ribavirin; Drug: pegylated interferon alpha and plus ribavirin; Drug: pegylated interferon alpha and plus ribavirin<br/><b>Sponsor</b>: Kaohsiung Medical University Chung-Ho Memorial Hospital<br/><b>Recruiting</b> - verified February 2007
|
|
